Market position NxThera’s Convective Water Vapor Energy platform targets endourology with BPH as the initial indication and is expanding into prostate and kidney cancer applications, indicating potential cross-sell opportunities to urology clinics seeking minimally invasive solutions and cancer treatment options.

Strategic partnerships Acquisition by Boston Scientific in early 2018 and ongoing Center of Excellence program illustrate strong channel access, credibility, and potential OEM or co-marketing partnerships to accelerate adoption and reimbursement conversations.

Clinical leverage Proven benefits in LUTS relief, urine flow, and quality of life position Rezûm as a differentiator in office-based or outpatient procedures, suggesting sales emphasis on outpatient urology practices and health systems prioritizing minimally invasive therapies.

Financial runway Funding of over 123 million and multi-round financing alongside revenue in the low to mid single digits signal scalable growth potential; target high-adoption clinics and centers with capital to invest in innovative devices.

Global exposure Active digital presence and a publicized professional ecosystem (Center of Excellence) provide reusable marketing assets and reference sites to support regional expansion, sales storytelling, and training programs for new markets.